Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (3): 259-262.doi: 10.3736/jcim20070306
• Commentary • Previous Articles Next Articles
Ren-gang Zhang1,2, Jun-ping Zhang1
CLC Number:
[1] |
Sztriha LK, Sas K, Vecsei L . Aspirin resistance in stroke: 2004. J Neurol Sci, 2005,( 229-230):163-169
doi: 10.1016/j.jns.2004.11.023 pmid: 3222215760636 |
[2] |
Weber AA, Zimmermann KC, Meyer-Kirchrath J , et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet, 1999,353(9156):900
doi: 10.1016/S0140-6736(99)00498-5 pmid: 10093990 |
[3] | Weber AA, Przytulski B, Schumacher M , et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol, 2002,117(2):424-426 |
[4] | Rocca B, Secchiero P, Ciabattoni G , et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA, 2002,99(11):7634-7639 |
[5] | Kimmel SE, Berlin JA, Reilly M , et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med, 2005,142(3):157-164 |
[6] | Johnsen SP, Larsson H, Tarone RE , et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med, 2005,165(9):978-984 |
[7] |
Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD , et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res, 2003,111(4-5):259-265
doi: 10.1016/j.thromres.2003.09.009 pmid: 14693173 |
[8] | Catella-Lawson F, Reilly MP, Kapoor SC , et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001,345(25):1809-1817 |
[9] |
Cryer B, Berlin RG, Cooper SA , et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther, 2005,27(2):185-191
doi: 10.1016/j.clinthera.2005.01.011 |
[10] |
Kong DF . Aspirin in cardiovascular disorders. What is the optimum dose. Am J Cardiovasc Drugs, 2004,4(3):151-158
doi: 10.2165/00129784-200404030-00002 pmid: 15134467 |
[11] | Helgason CM, Tortorice KL, Winkler SR , et al. Aspirin response and failure in cerebral infarction. Stroke, 1993,24(3):345-350 |
[12] | Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002,324(7329):71-86 |
[13] | Cox D, Maree AO, Dooley M , et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke, 2006,37(8):2153-2158 |
[14] | Macchi L, Christiaens L, Brabant S , et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res, 2002,107(1-1):45-49 |
[15] | Christiaens L, Macchi L, Herpin D , et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res, 2002,108(2-3):115-119 |
[16] | Mattiasson I, Lethagen S, Hillarp A . Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke. Int Angiol, 2003,22(3):239-242 |
[17] | Payne DA, Jones CI, Hayes PD , et al. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance. Thromb Haemost, 2004,92(1):89-96 |
[18] | Mirkhel A, Peyster E, Sundeen J , et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol, 2006,98(5):577-579 |
[19] | Macchi L, Christiaens L, Brabant S , et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1(GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak(GP Ibalpha) polymorphisms. J Am Coll Cardiol, 2003,42(6):1115-1119 |
[20] |
Gum PA, Kottke-Marchant K, Poggio ED , et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001,88(3):230-235
doi: 10.1016/S0002-9149(01)01631-9 pmid: 11472699 |
[21] | Jagroop IA, Mikhailidis DP . Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens, 2001,15(3):203-207 |
[1] | Dastan M. Khoshnaw, Abhijit A. Ghadge. Yoga as a complementary therapy for metabolic syndrome: A narrative review. Journal of Integrative Medicine, 2021, 19(1): 6-12. |
[2] | Morufu Eyitayo Balogun, Elizabeth Enohnyaket Besong, Jacinta Nkechi Obimma, Ogochukwu Sophia Mbamalu, Fankou Serges Athanase Djobissie. Protective roles of Vigna subterranea (Bambara nut) in rats with aspirin-induced gastric mucosal injury. Journal of Integrative Medicine, 2018, 16(5): 342-349. |
[3] | Chun-song Hu, Tengiz Tkebuchava. SEEDi1.0-3.0 strategies for major noncommunicable diseases in China. Journal of Integrative Medicine, 2017, 15(4): 265-269. |
[4] | Stephen D. Anton, Kacey Heekin, Carrah Simkins, Andres Acosta. Differential effects of adulterated versus unadulterated forms of linoleic acid on cardiovascular health. Journal of Chinese Integrative Medicine, 2013, 11(1): 2-10. |
[5] | Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210. |
[6] | Chit Moy Ley, Amalia Tsiami, Qing Ni, Nicola Robinson. A review of the use of bromelain in cardiovascular diseases. Journal of Chinese Integrative Medicine, 2011, 9(7): 702-710. |
[7] | Da-zhuo Shi, Hao Xu, Hui-jun Yin, Jing-chun Zhang, Ke-ji Chen. Combination and transformation of toxin and blood stasis in etiopatho-genesis of thrombotic cerebrocardiovascular diseases. Journal of Chinese Integrative Medicine, 2008, 6(11): 1105-1108. |